Involved in translocations

Articles

• FOXO1
  2 February 2007

  FKHR, FOXOA1
  Pathology
  PAX3-FOXO1 or PAX7-FOXO1 fusion genes in alveolar rhabdomyosarcoma
  Alveolar rhabdomyosarcoma (ARMS) is an aggressive neoplasm with unique t(2;13)(q35;q14) or t(1;13)(p36;q14) chromosomal translocations, resulting in PAX3/FOXO1 and PAX7/FOXO1 fusion genes, in approximately 80% of cases.
  These translocations and their gene fusions have not been identified in other neoplasms, making their identification an attractive target for applying ancillary diagnostic (...)

• MTG16
  29 September 2008

  Pathology
  Transcription co-repressor MTG16 modulates colitis and tumor development in inflammatory carcinogenesis. MTG16 is a tumor suppressor in colitis-associated carcinoma. doi:10.1172/jci.insight.78210.
  RUNX1-MTG16 fusion gene in acute myeloblastic leukemia (#18656694#) The significant homology between MGT16 and MTG8 suggests that the RUNX1-MTG16 fusion gene induced by the t(16;21)(q24;q22) is a variant of the RUNX1-MTG8 that shares similar activity.
  References
  De Braekeleer E, (...)

• RARA
  2 June 2004

  RAR-alpha steroid hormone receptor

• TAL2
  8 November 2005

  Pathology
  t(7;9)(q34;q32) in human T-cell leukemia (T-ALL)

• ETV1
  13 November 2005

  Pathology
  TMPRSS2-ETV1 fusion gene in prostate cancer ( prostatic adenocarcinoma ) (#16254181#)
  EWS-ETV1 fusion gene in Ewing sarcoma
  PTPRZ1-ETV1 fusion in gliomas (#31381204#)
  See also
  ETSs
  ETVs
  References
  Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 Oct (...)

• TMPRSS2
  14 November 2005

  Prostate cancer
  TMPRSS2 gene fusions with ETS transcription factor family members ERG, ETV1, or ETV4 have been recently discovered as a common molecular event in prostate cancer.
  Although several studies have been done, the clinical utility of TMPRSS2 genetic alterations as biomarkers for prostate carcinoma remains indeterminate.
  No normal prostate samples show TMPRSS2 translocation or deletion.
  Sixty-two percent (62%) patients of prostate carcinomas demonstrate TMPRSS2 gene (...)

• TLX1
  8 November 2005

  T-cell leukemia homeobox 1, HOX11, TCL3

• TAL1
  8 November 2005

  SCL, TCL5, T-cell acute lymphocytic leukemia 1

• BCL6
  17 February 2005

  LAZ3, ZNF51 WKP
  Definition: The BCL6 gene is a proto-oncogene, that encodes for a zinc-finger transcriptional repressor acting on a series of target genes implicated in T and B cell maturation, cell cycle control, apoptosis or inflammation.
  Its down regulation is necessary for the post-germinal center B cell maturation, whereas its expression is crucial for the germinal center formation.
  BCL6 is a zinc-finger transcription repressor normally expressed exclusively within GC B cells, (...)

• RANBP2
  29 March 2005

  Pathology
  Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in : ALK-associated inflammatory myofibroblastic tumor (#12661011#) at 2q11-q13 by t(2;2)(p23;q13) ALK-associated epithelioid inflammatory myofibroblastic sarcoma ( RANBP2-ALK )
  Open references
  A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
  Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, Katsushima U, Tsuya A, (...)

0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | ... | 140